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Summary. Mitotane is an important adrenalytic drug for 
the treatment of adrenal cancer whose use is limited by 
toxicity. Reports from another laboratory indicated that a 
methylated homolog of Mitotane (Mitometh) tested in 
guinea pigs possessed comparable adrenalytic activity but 
was less toxic than Mitotane. This observation prompted us 
to undertake a comparative study of these two drugs on the 
basis that Mitometh may be a superior agent for the treat- 
ment of adrenal cancer. Preliminary studies in guinea pigs 
failed to show a significant adrenalytic effect for either 
Mitotane or Mitometh. Thus, we extended the study to 13 
mongrel dogs weighing 12-15 kg that were treated daily 
with Mitometh or Mitotane (50-100 mg/kg) for 6 or 
12 days. Cortisol decreased to undetectable levels and 
adrenocorticotropic hormone (ACTH) rose to 10 times the 
baseline levels within 72 h in Mitotane-treated animals. 
Despite the achievement of similar drug levels, Mitometh 
treatment in dogs failed to suppress cortisol or increase 
ACTH. To determine whether these differences were due 
to differences in bioavailability, we measured the relative 
concentration of Mitotane and Mitometh in homogenates 
of adrenal cortex obtained from Mitotane- and Mitometh- 
treated dogs. The adrenal concentration of Mitometh deter- 
mined in Mitometh--treated dogs was 5 times higher than 
the concentration of Mitotane measured in Mitotane- 
treated animals. Whereas the adrenal glands of Mitotane- 
treated dogs showed hemorrhage and necrosis, the Mi- 
tometh-treated animals showed no adrenal damage. De- 
spite the lack of adrenalytic activity, Mitometh maintained 
its toxicity as demonstrated by microscopic evidence of 
hepatic necrosis and an increase in hepatic enzymes. The 
adrenalytic effects of both agents was also studied in vitro 
using a human functioning adrenal cortical carcinoma cell 
line, NCI-H295. Whereas Mitotane strongly suppressed 
cell growth, Mitometh had a weaker effect. We conclude 
that Mitometh is not likely to be effective in the therapy of 
adrenal cancer. Moreover, the results of this study are 
supportive of the view that metabolic transformation of 
Mitotane is in some way linked to its adrenalytic action. 
Introduction 
Mitotane [ 1-(o-chlorophenyl)- 1-(p-chlorophenyl)-2,2-di- 
chloroethane; o,p'-DDD] is an adrenalytic drug used in the 
treatment of adrenal cancer and benign Cushing's syn- 
drome whose application is limited by toxicity. Mitotane's 
activity appears to depend on its metabolism. In vitro stud- 
ies [15] using adrenal cell mitochondria suggested that 
Mitotane's activity required metabolism and covalent 
binding to cell macromolecules, but this requirement had 
not been demonstrated in vivo. Jensen et al. [13] reported 
that in the guinea pig, Mitometh [ 1-(o-chlorophenyl)-1-(p- 
chlorophenyl)-2,2-dichloropropane], a methylated analog 
of Mitotane, was capable of inducing ultramicroscopic 
changes in adrenocortical cells similar to those caused by 
Mitotane but was not as toxic, making it an attractive 
candidate for use in adrenal cancer. Since Mitometh, in 
contrast to Mitotane, is incapable of forming the acid me- 
tabolite o-chlorophenyl-p-chlorophenyl acetic acid (o,p'- 
DDA), the studies by Jensen et al. seemed to negate the 
importance of metabolism of the -CHC12 moiety as a re- 
quirement for the adrenalytic activity of Mitotane. To 
study the activity of Mitometh and its possible use in 
adrenal cancer, we compared the adrenalytic activity of 
Mitometh and Mitotane both in vivo in guinea pigs and 
dogs with normal adrenal function and in vitro on a 
functioning human adrenal cortical carcinoma cell culture. 
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Materials and methods 
Compounds. Mitotane (USP grade) was obtained from Bristol Myers. 
Mitometh was synthesized using a modification of the procedure of 
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Fig. 1. Chemical structures of Mitotane and Mitometh 
used to establish the standard curve. Values for the unknown samples 
were read off the standard curve. 
Measurement of serum aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), cholesterol, and alkaline phosphatase was car- 
ried out using Beckman Autoanalyzer methods. AST and ALT are mea- 
sured photometrically by the use of a reduced nicotinamide adenine 
dinucleotide (NADH)-coupled reaction; the alkaline phosphatase proce- 
dure uses p-nitrophenylphosphate (p-NPP) as the substrate, carbonate-bi- 
carbonate as the buffer, and glycerol as the phosphate acceptor. 
Jensen et al. [13] (Fig. 1). The crude product was purified by column 
chromatography (silica with hexane). This afforded 5.33 g of a clear oil 
(85%) that crystallized upon standing. Recrystallization from methanol 
gave a pure product with a melting point of 54~ ~ C. The nuclear 
magnetic resonance of the crystalline product agreed with the values 
reported by Jensen and co-workers [13]. Thin-layer chromatography 
indicated a single spot (Rf, 0.29) in cyclohexane. The analytical data 
calculated for C15H12Ch were: C, 53.93%; and H, 3.62%. The values 
found were: C, 54.03%; and H, 3.53%. The final Mitometh product used 
in animal studies was found to be 97% pure by thermal analysis with the 
presence of <0.6% Mitotane and 2.4% unsaturated Mitometh [1-(o- 
chlorophenyl)- 1-(p-chlorophenyl)-2-chloro- 1-propene] as determined by 
gas chromatographic analysis. 
Assays. Serum cortisol was measured by a solid-phase t251 radioim- 
munoassay (Coat-A-Count; Diagnostic Products). The sensitivity of this 
assay is 0.2 gg/dl and the specificity is 97% (the cross-reactivity with 
prednisolone is 46% and that with prednisone is 3.1%). 
Plasma adrenocorticotropic hormone (ACTH) levels were deter- 
mined by radioimmunoassay (RIA) by the method of Vague et al. [27] 
using a very sensitive and specific antibody at a dilution of 1 : 800,000. 
This antibody has low cross-reactivity with other peptides and is capable 
of detecting ACTH in plasma at concentrations as low as 6 pg/ml. Sepa- 
ration of free from bound hormone was canfed out with a 1.5% charcoal 
suspension. The tracer was prepared using human ACTH 1-39 
(Peninsula Laboratories) and iodinated with ~25I by the chloramine-T 
method [ 12]. Plasma samples were stored a t -80~ until assay with loss 
of tess than 10% activity within 1 yea. ACTH was measured in unex- 
tracted plasma and each sample was run in four dilutions. Quality-control 
studies were carried out with each assay using standard sera and carry- 
over samples from previous assays with high, intermediate, and low 
ACTH concentrations. The coefficient of variation for this assay is 
4.2% 4-1.2% for 20% binding and 8.4% _+2.4% for 80% binding. 
Serum and tissue levels of Mitotane and Mitometh were determined 
by gas chromatography (GC-EC). Serum levels were obtained at 2 h 
following the first daily drug dose. To 100+tl aliquots of serum, 10 pl of 
an internal-standard methanol solution containing 1-(o-chlorophenyl)-1- 
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(p-chlorophenyl)-2,2-dichloroethylene (o,p -DDE) at a concentration of 
8.88-44.4 g/ml was added. Standards were prepared using increasing 
concentrations of Mitotane or Mitometh in methanol solution, 100 gl 
control plasma from sesame oil-treated dogs, and 10 gl o,p'-DDE in 
methanol as the internal standard. To both samples and standards, 100 gl 
formic acid was added to denature proteins. Samples were extracted with 
1,5 ml high-performance liquid chromatography (HPLC)-grade hexane 
and centrifuged at 1700 g for 6 rain. Adrenal glands obtained from 
treated and control dogs anesthetized with sodium pentobarbital 
(30 mg/kg) were trimmed of fat and connective tissue and the cortex was 
separated and homogenized. The homogenate was extracted with 
ether/methanol and the extracts were combined, evaporated to dryness, 
and reconstituted in hexane for analysis; 10 gl o,p'-DDE in methanol was 
added as the internal standard. Aliquots (1 gl) of hexane supernatant of 
each sample and standard solutions and of the adrenal extract were 
injected into a Varian 3700 gas chromatograph equipped with a 63Ni 
electron-capture detector and a glass column (2 m x 2 mm inside diam- 
eter) containing 3% OV-101 on gas-chrom Q (80-100 mesh). The 
conditions were: column temperature, 215~ injection temperature, 
250~ and detector temperature, 300~ Nitrogen was used as the 
carrier gas. Peak/height ratios of Mitotane or Mitometh to o,p'-DDE were 
In vivo studies. Studies were initially carried out in female Hartley guinea 
pigs weighing 300-400 g since Jensen et al. [13] had reported adrena- 
Iytic effects of Mitotane and Mitometh in this animal species. Because of 
the well-known adrenalytic effect of Mitotane, this drug was tested first. 
Oral treatment at levels of 150 and 300 mg/kg daily in corn-oil emulsion 
for 4 weeks failed to show any significant suppressive effect on cortisol 
levels or gross adrenal changes. It was also noted that Mitotane blood 
levels were barely measurable when obtained at 2 h following drug 
administration. These levels became easily measurable when the oral 
dose was increased to 1200 mg/kg daily. At this dose level, cortisol 
values did not decrease but the animals developed weight loss, diarrhea, 
lethargy, and alopecia. In view of the relatively poor absorption from the 
oral dose, Mitotane was reformulated in Tween-80 and 0.9% saline for 
intraperitoneal (i. p.) injection. Better absorption and higher blood levels 
were noted when 150 and 300 mg/kg Mitotane were given as a single 
injection. Chronic administration of these two doses for a period of 
2 weeks caused weight loss, diarrhea, lethargy, and alopecia, and all 
animals died before the completion of the study. Cortisol levels during 
treatment were elevated, suggesting stress effects. 
Since the i. p. injection of Mitotane in Tween-80 and saline was better 
absorbed and caused greater toxic side effects, both Mitotane and Mi- 
tometh were then tested. Doses of 50 and 100 mg/kg Mitotane or Mi- 
tometh were given daily by i.p. injection for 2 weeks. The previously 
described side effects occurred in all animals but were most severe 
during treatment with Mitometh. Serum cortisol levels increased 
dramatically in all treatment groups. Serum drug levels were higher in the 
Mitometh-treated animals. Mitometh was then formulated in Tween-80, 
saline, and syrup and was given orally at doses of 75 mg/kg daily for 
4 weeks. The drug was tolerated without toxicity and high blood levels 
were obtained. Cortisol levels did not change and histologic examination 
of the adrenal glands failed to reveal any significant adrenalytic effect. In 
view of the lack of significant suppressive effects on cortisol levels or 
histologic adrenal changes with either Mitotane or Mitometh in the 
guinea pig, we switched to maIe mongrel dogs weighing 12-15 kg since 
dogs had been found to be the most sensitive species to the adrenalytic 
effect of Mitotane [ 15]. 
Dogs were treated with Mitotane or Mitometh in sesame oil solution 
given orally in capsule form. Blood samples were obtained daily for 
determination of cortisol, ACTH, and drug levels. Biochemical indices of 
tiver function were obtained on the last day of treatment. The treatment 
was continued for periods of 6 - 1 2  days, and the dogs were adrenalec- 
tomized and subsequently euthanized on the day following the last dose. 
In each experiment, one dog was used as a control and received sesame 
oil capsules at the same frequency as did the animals receiving the drug. 
Samples of adrenal glands and livers were fixed in 10% neutral 
buffered formalin and embedded in paraffin. Sections stained with he- 
matoxytin and eosin were evaluated for evidence of tissue damage. 
In vitro studies. The adrenalytic potential of Mitotane and Mitometh in 
human adrenal cancer was compared in vitro using a steroid hormone- 
secreting human adrenocortical carcinoma cell line, NCI H-295 [9]. Cells 
were maintained at 37~ with 5% CO2 in RPMI 1640 medium supple- 
mented with 5 gg insulin fi'om bovine pancreas/ml (24 IU/ml), 10 gg 
human transferrin/ml, 2 m~ glutamhle, 10 nM hydrocortisone, 10 nM 
estradiol, 50 nM sodium selenite, 100 units penicillin/M, 0.1 mg strepto- 
mycin/M, 250 ng amphotericin B/ml, and 5% fetal bovine serum. Cells 
were harvested for subculturing and for experiments using 0.05% porcine 
trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA) in Hank's 
balanced salt solution. All medium components and trypsin/EDTA were 
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Fig. 2. A Fall in serum cortisol and 
B rise in plasma ACTH levels in three 
dogs during treatment with Mitotane at 
47 mg/kg daily for 6 days. Dogs were 
killed (sac) on the 7th day 
Lion of cell-growth inhibition, 10,000 cells/well were dis~ibuted into 
96-well plates and incubated for 7 days. Then the drugs were dissolved in 
ethanol and added to the wells to obtain the desired concentrations. 
Incubation was continued for an additional 7 days, after which the me- 
dium was sampled for determination of cortisol concentration using the 
assay described above for serum. Cell growth was evaluated by measur- 
ing the relative protein content of the cell cultures using the sulforho- 
damine B assay [26] on the day on which drugs were added and on the 
7th day of drug treatment. The cortisol concentration and the number of 
cell doublings in wells to which the drugs had been added were expressed 
as a percentage o~ ~he results obtained in control wells in the absence of 
drug. 
Results 
In vivo studies 
Adrenalytic effect. A total of 13 dogs were treated with 
either Mitotane or Mitometh. Figure 2 A depicts the fall in 
cortisol levels during treatment with Mitotane (47 mg/kg 
daily) in three dogs. These levels did not rise at the time of 
euthanasia in spite of a marked increase in ACTH values. 
Figure2B shows that ACTH levels rose steadily 
throughout the study to 5 times the baseline values, with a 
large response occurring at the time of euthanasia, consis- 
tent with a hypothalamic-pituitary response to stress. Fig- 
ure 3 compares the response to Mitotane and Mitometh in 
sesame oil in two dogs treated with these drags at doses of 
47 mg/kg daily for 6 days. A third dog received the vehicle 
alone. As depicted in Fig. 3 A, in the dog treated with 
Mitotane, serum cortisol levels declined steadily over 48 h 
and remained at very low levels throughout the study. At 
the time at which the animals were killed, serum cortisol 
levels remained suppressed. In contrast, the dog treated 
with Mitometh maintained cortisol levels in a range similar 
to that of the control dog. Figure 3 B depicts the ACTH 
response during treatment with Mitotane or Mitometh. 
Whereas the Mitotane-treated dog showed a steady in- 
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Fig. 3A, B, Contrast in the A cortisol 
and B ACTH response to treatment with 
Mitotane or Mitometh at 47 mg/kg 
daily for 6 days. The control dog re- 
ceived sesame oil capsules. Whereas 
Mitotane promptly suppressed adrenal 
function, Mitometh treatment had no 
significant effect 
in cortisol and development of adrenocortical insuffi- 
ciency, the values measured in the Mitometh-treated dog 
remained at baseline levels throughout the study in a man- 
ner similar to that observed for the control dog. In spite of 
this very different response, blood levels of Mitotane 
(day 5, 4.4 gg/ml; day 6, 5.9 gg/ml) and Mitometh (day 5, 
5.3 gg/ml; day 6, 5.9 gg/ml) were comparable in the two 
animals. Additional studies using Mitometh in three dogs 
at 89 mg/kg daily for 6 days or in another four dogs at the 
same daily dose for 12 days failed to change either cortisol 
or ACTH levels significantly. The drug concentration in 
the adrenal cortex of these dogs following treatment was 
also measured. The mean ( _+ SD) Mitometh concentration 
determined after Mitometh treatment (171.2 + 11.1 gg/g 
wet weight) was much higher than the Mitotane concentra- 
tion measured after Mitotane treatment (69.7+2.5 gg/g 
wet weight). The difference in response was therefore not 
due to differences in blood or tissue drug concentrations. 
Figure 4 depicts the histologic changes observed in the 
adrenal glands of dogs treated with Mitotane or Mitometh 
as compared with the gland of a control dog (Fig. 4A). 
Whereas Mitotane treatment was associated with signifi- 
cant necrosis and hemorrhage (Fig. 4B), Mitometh 
(Fig. 4 C) produced no significant histologic effect. 
Drug toxicity. Blood samples for measurement of AST, 
ALT, total cholesterol, and alkaline phosphatase were ob- 
tained before and on the last day of drug treatment. In spite 
of its lack of adrenalytic effect, Mitometh treatment was 
associated with a decrease in cholesterol and alkaline 
phosphatase values and a marked increase in SGPT and 
SGOT levels, consistent with hepatoxicity (Table 1). In 
contrast, the changes observed during treatment with Mi- 
totane were much milder. Histologic examination of the 
livers revealed no significant abnormality in the Mitotane- 
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Fig. 4 A. Adrenal cortex of a sesame oil-treated con- 
trol. The capsule is at the left and the medulla, to the 
right. All zones of the cortex (G, glomerulosa; F, 
fasciculata; R, reticularis) are intact and show no 
evidence of inflammation. Hematoxylin and eosin, 
x 120. Fig. 4B, Adrenal cortex of a Mitotane- 
treated dog, oriented as in Fig. 4 A. Adjacent to the 
medulla, a dense infiltrate of inflammatory cells 
(large arrows) is evident in the deep cortex, which 
has undergone extensive necrosis. Similar dark 
areas of inflammatory cellular infiltrate (small ar- 
rows) also extend toward the capsule. Hematoxylin 
and eosin, x 120. Fig. 4 C. Adrenal cortex of a Mi- 
tometh-treated dog, oriented as in Figs. 4 A and 4 B. 
All zones of the cortex are intact and show no evi- 
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Fig.  5 A, B. Comparison of the inhibition of A cortisol production and 
B cell doubling by 5 - 5 0  gM Mitotane ( 0 )  and Mitometh ( 9  in H-295 
cells in vitro. Cells were incubated for 7 days after drug addition, then 
cortisol concentration and cell doubling were measured. During these 
7 days in control cultures, cortisol production resulted in a concentration 
of 270 r ~  in the medium, and the cells doubled 1.5 times. These are 
average control values. The cortisol concentration and cell doublings in 
the drug-treated cultures are expressed as a percentage of the control 
values within each experiment. The values shown are the averages of the 
values obtained in two independent experiments, which differed by less 
than 30%. The concentration required to inhibit cortisol production and 
cell doubling by 50% (IC50) was derived graphically for each drug 
treated animals, but, corresponding to the biochemical data 
in Table 1, the livers of Mitometh-treated dogs showed 
microvesicular steatosis and spotty hepatocellular necrosis. 
In vitro studies 
Figure 5 compares the response of H-295 adrenal cancer 
cells to Mitotane and Mitometh after a 7-day incubation 
period. Mitotane had a marked suppressive effect on corti- 
sol concentration (Fig. 5A) and cell doubling (Fig. 5 B), 
affecting both similarly at a 50% inhibitory concentration 
(ICs0) of 20 and 24 gM, respectively. Thus, the suppression 
of cortisol production by Mitotane in vitro can be ac- 
counted for by the suppression of cell growth alone without 
any effect on the amount of cortisol produced per cell. 
These results are consistent with the conclusion that in the 
concentration range studied, Mitotane suppresses cell 
Table  1. Biochemical side effects of treatment with Mitometh at 
89 mg/kg for 12 days 
Dog1 Dog2 Dog3 
B Rx B Rx B Rx 
Cholesterol 131 98 153 16 222 67 
Alkalinephosphatase 113 1298 20 936 39 978 
ALT 25 148 25 279 30 127 
AST 23 65 23 130 15 55 
B, Baseline; Rx, after drug therapy 
growth but does not directly inhibit cortisol synthesis. Mi- 
tometh had a similar but consistently weaker (not statisti- 
cally significant) effect at IC50 values of 31 gM for cortisol 
and 44 gM for cell doubling. Interestingly, Mitometh ap- 
pears to have a direct effect on cortisol production, as it 
inhibited the cortisol concentration more strongly than it 
did cell growth. 
D i s c u s s i o n  
The studies described herein indicate that contrary to the 
initial studies by Jensen and co-workers [13], Mitometh 
does not exert adrenalytic effects in either the guinea pig or 
the dog. This is in contrast to the well-known adrenalytic 
effect of its parent compound, Mitotane. The lack of adren- 
alytic effect was noted in spite of the increased uptake and 
concentration of Mitometh in the dog adrenal. Since the 
methylation of Mitotane blocks its ability to undergo trans- 
formation to DDA, our findings are in agreement with 
those proposed by Martz and Straw [15], which suggest 
that metabolism is required for the adrenalytic effect. As an 
extension of this hypothesis, our studies indicate that a C-H 
needs to be preserved at the C-2 position in the aliphatic 
portion of the molecule. Accordingly, metabolism for Mi- 
totane would involve hydroxylation at C-2 and, following 
dehydrochlorination, the formation of a transient acyl chlo- 
ride (Fig. 6) that would be capable of acetylating important 
macromolecules in the adrenal cortical cell 
Supporting the need of metabolic transformation for 
activity are studies [15] showing that dog adrenal mito- 
chondria metabolize Mitotane to reactive products that co- 
valently bind to mitochondrial macromolecules. The level 
of metabolism and covalent binding of [14C]-Mitotane was 
greater in dog adrenals than in those of the guinea pig, 
rabbit, or rat, and it correlated with the known sensitivity of 
these species to the adrenalytic effect of the drug, with the 
dog being the most sensitive and the rat, the least sensitive 
species. The relative insensitivity of the guinea pig to Mi- 
totane probably explains in part the failure to observe sig- 
nificant adrenalytic effects in this animal model. Another 
explanation for the lack of response was poor absorption as 
indicated by undetectable serum drug levels following oral 
administration. Jensen et al.'s report on the effects of Mi- 
totane and Mitometh did not include measurement of 
adrenal function or histologic changes on light microscopy. 
The effects described occurred only at the ultramicroscopic 
level and were probably very mild. The Mitometh used in 
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Fig. 6. Postulated metabolic transformation 
of Mitotane with the formation of an acyl 
chloride 
our study was prepared by a modification of the method of 
Jensen et al. [13], which afforded a crystalline product 
rather than an oil. Despite recrystallization, the final prod- 
uct contained 2.6% of the product arising from the dehy- 
drochlorination. Because of the possibility that this unsatu- 
rated analog of Mitometh might have been responsible for 
the results obtained by Jensen et al., dogs were treated with 
this compound for 6 days without significant adrenalytic 
effect. 
The importance of an intact C-H at the C-2 position of 
the aliphatic portion of the molecule is supported by the 
experience with 26 DDD analogs previously tested [1-3, 
5, 6 - 8 ,  11, 14, 16 -19]. These studies indicate that cyto- 
toxic adrenal effects are most consistently associated with 
a dihalogenated ethane structure. The adrenalytic effect of 
Mitotane is lost if the H is replaced by a chlorine as in 
o,p'-DDT and other trichlorinated analogs of Mitotane [5, 
7]. In contrast, substitutions in the benzene rings are less 
critical in determining adrenalytic effects. 
Although the nature of the active metabolites involved 
and the mechanism by which they exert their adrenalytic 
effect remains to be defined, studies from our laboratories 
have demonstrated metabolic oxidation of both the aro- 
matic and the aliphatic portions of Mitotane in rats [21 ] and 
in humans [23]. In addition, our in vitro studies have 
shown aliphatic oxidation in bovine adrenal incubations 
[22] as well as aromatic hydroxylation and side-chain oxi- 
dation in perfusion studies of dog adrenals [25]. It is possi- 
ble that the mechanism of adrenal cytotoxicity may involve 
a cytochrome P-450 enzyme-mediated metabolic activa- 
tion in a process similar to that undergone by other dihalo- 
genated-ethane compounds where acyl halides would be 
the reactive intermediates. Studies in mice and hamsters 
suggest this mechanism for the formation of p,p'-DDA 
from 1,l-his (p-chlorophenyl) 2,2-dichloroethane (p,p'- 
DDD) [ 10]. Another example is the metabolic activation of 
chloramphenicol (CAP), a compound with partial structur- 
al homology with Mitotane. Studies of the metabolic acti- 
vation of CAP by rat-liver microsomes [20] suggest the 
involvement of a cytochrome P-450-activating system. 
The proposed mechanism is that the C-H bond of the 
dichloromethyl carbon is oxidized and the hydroxylated 
metabolite is spontaneously dehydrochlorinated to produce 
an oxamyl chloride derivative. This reactive metabolite 
reacts with microsomal protein to cause cytotoxic effects. 
A similar mechanism appears to apply to other chlorinated 
compounds such as halothane and chloroform [4]. Because 
of the transient nature of the acyl chloride, direct studies to 
confirm this mechanism have not been forthcoming. 
The effect of Mitometh on human adrenal cortical carci- 
noma cells in vitro is also of interest. Mitometh suppressed 
both cortisol production and cell doubling. This response 
differed from the lack of cortisol suppression and adrena- 
lytic effect observed in dogs in vivo. It is unlikely that 
differences in bioavailability played a role in these differ- 
ent responses since the concentration of Mitometh 
achieved in the dog adrenals was much higher than that of 
Mitotane. Other mechanisms may explain this discrepancy. 
The in vivo studies were conducted in normal dogs, where- 
as the in vitro studies were carried out in human adrenal 
cancer cells. These cells may respond to Mitometh by 
mechanisms that do not require metabolic transformation. 
Although Mitotane is effective as an adrenalytic drug, 
its use is limited by side effects. In a study of 26 patients 
with pituitary ACTH-dependent Cushing's syndrome 
treated with cobalt irradiation of the pituitary gland and 
low-dose Mitotane chemotherapy, we observed [24] that 
88% of the patients developed anorexia and nausea; 38%, 
diarrhea; and 23% vomiting. In all, 50% of the patients 
complained of neurologic symptoms associated with a 
decreased in memory and in the ability to concentrate. Skin 
rashes, arthralgias, and leukopenia were observed in a 
smaller percentage of patients. There were also a variety of 
biochemical side effects, including hypercholesterolemia, 
hypouricemia, and increased liver enzymes. Clearly there 
is a need for a better drug for the treatment of patients 
suffering from adrenal cancer. Unfortunately, Jensen et 
al.' s observations that Mitometh was more adrenalytic and 
less toxic than Mitotane have not been confirmed in these 
studies. In fact, toxicity persisted in spite of the lack of 
adrenalytic effects, and hepatic necrosis during treatment 
with Mitometh was clearly present. Because of its toxicity 
and its weak adrenalytic effect on adrenal cancer in vitro, 
Mitometh is not likely to be of utility in the treatment of 
adrenal cancer. The present studies provide supporting evi- 
dence of the requirement for metabolic transformation at 
C-2 of Mitotane for the production of adrenalytic effects. 
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